Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sanofi to buy hepatitis vaccine maker Dynavax in $2.2bn deal

(Sharecast News) - France's Sanofi said on Wednesday that it has agreed to buy US hepatitis vaccine maker Dynavax in a $2.2bn deal. Dynavax's adult hepatitis B vaccine is currently marketed in the US, while its shingles vaccine candidate is in phase 1/2 clinical development.

The company said the acquisition augments its presence in adult immunisation by bringing together Dynavax's vaccines with Sanofi's "global scale, development capabilities and commercial reach".

Under the terms of the deal, Sanofi will start a cash tender offer to buy all outstanding shares of Dynavax for $15.50 per share.

Thomas Triomphe, executive vice president of vaccines at Sanofi, said: "Dynavax enhances Sanofi's adult immunisation presence by adding differentiated vaccines that complement Sanofi's expertise.

"Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan."

The acquisition, which is due to close in the first quarter of next year, is not expected to have any impact on Sanofi's financial guidance for 2025.

Share this article

Related Sharecast Articles

Iforex reviving plans for £40m London float - report
(Sharecast News) - Financial trading company Iforex is reportedly reviving plans for a £40m London stock market listing.
Sky deal talks with ITV have slowed - report
(Sharecast News) - Sky's talks with London-listed broadcaster ITV about buying its broadcast channels and streaming platform have reportedly slowed in recent weeks, as the battle to buy Warner Bros Discovery disrupts the industry.
Diverse Income Trust underperforms benchmark
(Sharecast News) - The Diverse Income Trust said on Friday that it underperformed its benchmark index in the six months to 30 November 2025, as its tilt towards smaller companies proved to be a headwind.
Berenberg hikes target price on Morgan Sindall
(Sharecast News) - Analysts at Berenberg hiked their target price on construction firm Morgan Sindall from 5,400p to 5,800p on Friday in order to reflect another strong performance from the group's fit out division.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.